Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting

Published:2017-04-21 Issue:1 Volume:4 Page:15-22
ISSN:2055-6837
Container-title:European Heart Journal - Cardiovascular Pharmacotherapy
language:en
Short-container-title:

Author:

Korman Max¹,Wisløff Torbjørn¹²

Affiliation:

1. Department of Health Management and Health Economics, The Faculty of Medicine, University of Oslo, Postboks 1089, Blindern, 0317 Oslo, Norway

2. Norwegian Institute of Public Health, Infectious Diseases Epidemiology and Modelling, Postboks 4404, Nydalen, 0403 Oslo, Norway

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/ehjcvp/article-pdf/4/1/15/24194364/pvx010.pdf

Reference34 articles.

1. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials;Lancet,2010

2. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines;Stone;J Am Coll Cardiol,2014

3. ESC/EAS Guidelines for the management of dyslipidaemias;Reiner;Eur Heart J,2011

4. PCSK9 inhibitors: a technology worth paying for?;Weintraub

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of CETP, PCSK-9, and CYP7-alpha in cholesterol metabolism: Potential targets for natural products in managing hypercholesterolemia;Life Sciences;2024-08

2. The Causal-Benefit Model to Prevent Cardiovascular Events;JACC: Advances;2024-03

3. Inclisiran;Clinical Lipidology;2024

4. Lost Therapeutic Benefit of Delayed Low-Density Lipoprotein Cholesterol Control in Statin-Treated Patients and Cost-Effectiveness Analysis of Lipid-Lowering Intensification;Value in Health;2023-04

5. Familial Hypercholesterolaemia as a Predisposing Factor for Atherosclerosis;Biomedicines;2022-10-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3